影响他克莫司浓度的药物遗传学研究进展  

Progress in pharmacogenetic studies on effect on tacrolimus concentrations

作　　者：杨爽[1] 王力宁[1] YANG Shuang;WANG Li-ning(Department of Nephropathy,the First Hospital Affiliated to Chinese University of Medicine,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院肾内科,沈阳110001

出　　处：《临床肾脏病杂志》2020年第9期752-757,共6页Journal Of Clinical Nephrology

基　　金：国家自然科学基金(No.81370870)。

摘　　要：他克莫司药代动力学及药效动力学参数代谢个体差异大,治疗窗窄,是导致排斥或毒性反应的主要原因,其中遗传因素是引起他克莫司代谢个体差异的主要原因之一。本文就影响他克莫司血药浓度的遗传因素(主要包括代谢酶基因多态性及药物转运蛋白基因多态性)进行综述,从而为临床实现他克莫司个体化治疗提供参考。The pharmacokinetic and pharmacodynamic parameters of tacrolimus have big individual differences,and the drug has a narrow treatment window.These are main causes leading to rejection and toxic reactions,and hereditary factors are one of main causes for individual difference of tacrolimus efficacy.In this paper,we review the hereditary factors which affect tacrolimus concentrations,mainly including metabolic enzyme gene polymorphism and dry delivery protein gene polymorphism,so as to provide reference for achievement of clinical individualized treatment with tacrolimus.

关 键 词：他克莫司 药物遗传学 基因多态性 CYP3A5 CYP3A4 

分 类 号：R969.1[医药卫生—药理学]